Form 4: Regeneron Director Exercises Options, Sells Shares

Regeneron Pharmaceuticals Director Christine A. Poon exercised stock options and subsequently sold a portion of her common stock holdings in late October 2025.

Summary

• Christine A. Poon, a Director at Regeneron Pharmaceuticals, Inc., engaged in multiple transactions involving the company's common stock.
• On October 29, 2025, Poon exercised non-qualified stock options to acquire 6,500 shares of common stock at an exercise price of $520.01 per share.
• Immediately following the option exercise on October 29, 2025, Poon sold a total of 6,490 shares of common stock in multiple transactions at volume-weighted average prices ranging from $652.68 to $657.29.
• On October 30, 2025, Poon exercised additional non-qualified stock options to acquire 2,712 shares of common stock at an exercise price of $520.01 per share.
• Following these transactions, Poon's direct beneficial ownership of common stock decreased from 8,852 shares (after the first option exercise) to 2,352 shares (after the sales) and then increased to 5,064 shares (after the second option exercise).
• The non-qualified stock options vested in three equal annual installments, commencing one year after the date of grant.

Sentiment

Score: 6

Explanation: The director exercised options and sold shares at a profit, which is positive for the individual. However, the net reduction in direct holdings could be viewed neutrally or slightly negatively by some investors, though it's a common practice for diversification or tax planning.

Positives

• Director Christine A. Poon exercised stock options at $520.01, indicating a belief in the stock's value above this price.
• The subsequent sales of common stock occurred at prices significantly higher than the exercise price, ranging from $652.68 to $657.29, realizing a profit for the director.

Negatives

• Director Christine A. Poon sold a substantial number of shares (6,490 shares) after exercising options, which could be interpreted as a reduction in her direct equity exposure to the company.

Future Outlook

NA

Industry Context

This filing reports routine insider transactions and does not provide broader industry context or strategic updates for the pharmaceutical sector.

Related Party Transactions

• Director Christine A. Poon engaged in transactions involving the company's common stock, including exercising stock options and selling shares.

Stakeholder Impact

• Shareholders may interpret the sales as a slight reduction in insider confidence, or as routine diversification and personal financial management.

Key Dates

Recommendation

The filing details routine insider transactions where a director exercised stock options and subsequently sold shares for a profit. This type of transaction, while reducing the director's direct equity holdings, is common for diversification or tax planning and does not inherently signal a change in the company's fundamental outlook or warrant a strong buy or sell recommendation based solely on this report.

Keywords

Regeneron, REGN, insider trading, stock options, common stock, director, SEC Form 4, pharmaceutical